Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia

Br J Haematol. 2013 Oct;163(2):286-9. doi: 10.1111/bjh.12483. Epub 2013 Jul 17.
No abstract available

Keywords: eltrombopag; immune thrombocytopenia; romiplostim.

Publication types

  • Letter

MeSH terms

  • Benzoates / therapeutic use
  • Drug Resistance
  • Drug Substitution
  • Humans
  • Hydrazines / therapeutic use
  • Purpura, Thrombocytopenic, Idiopathic / drug therapy*
  • Pyrazoles / therapeutic use
  • Receptors, Fc / administration & dosage
  • Receptors, Fc / therapeutic use*
  • Receptors, Thrombopoietin / agonists
  • Recombinant Fusion Proteins / administration & dosage
  • Recombinant Fusion Proteins / adverse effects
  • Recombinant Fusion Proteins / therapeutic use*
  • Thrombopoietin / administration & dosage
  • Thrombopoietin / adverse effects
  • Thrombopoietin / therapeutic use*
  • Treatment Outcome

Substances

  • Benzoates
  • Hydrazines
  • Pyrazoles
  • Receptors, Fc
  • Receptors, Thrombopoietin
  • Recombinant Fusion Proteins
  • Thrombopoietin
  • romiplostim
  • eltrombopag